Insider buying last 90 days
No open-market insider purchases were filed for PBH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PBH insider filing, plotted on the chart in Gekko.Open PBH in Gekko
NYSE: PBH
Prestige Consumer Healthcare (PBH) Stock Analysis & Forecast
Oct 12 close
$49.00+0.77 (+1.6%)
Gekko Brief
AI summaryOct 12 closePrestige Consumer Healthcare's week centers on a major portfolio move: the company completed the acquisition of the Breathe Right brand and related brands from Foundation Consumer Healthcare for $1.045 billion, a deal that includes $150 million in tax benefits and makes Breathe Right the largest brand in its lineup. Alongside this, Prestige priced a private offering of $400 million in 6.25% senior notes due 2034, with proceeds set to redeem its existing $400 million 5.125% notes due January 2028. Results commentary in the period points to a Q4 2026 revenue decline of 5% year-over-year, with weakness in North America OTC Eye & Ear Care and International OTC segments, alongside separate reporting of a 6.5% sales increase to $266 million in Q1 2027, driven by GI and skincare performance and contributions from the Breathe Right and Locorium Health acquisitions.
PBH closed at $49.00, up 1.6%, sitting below both its 50-day average of $49.51 and its 200-day average of $55.11. The GekkoIndex reads 54.6, placing the stock in the Neutral zone. Against this, Gekko Fair Value stands at $90.45, putting the current price 45.8% below that level.
The next earnings date falls on 5 November 2026, before the open, 24 days away and within a typical 20-trading-day holding window; the prior quarter saw an adjusted EPS of $1.14 against a $1.16 estimate, with a -1% reaction. No insider, Congress or unusual options activity appears in the recent window. Seasonality for this calendar stretch has averaged a 7.3% move over the next 20 trading days across 5 years, rising in 4 of them. One covering firm currently rates the stock a buy, with a consensus target of $67.8.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Prestige Consumer Healthcare price vs fair value
Close $49.00200-day averageGekko Fair Value $90.45
Prestige Consumer Healthcare quick facts
- Market cap
- $2.32B
- P/E ratio
- 13.5
- Forward P/E
- 10.6
- EPS, TTM
- $3.57
- Revenue, TTM
- $1.10B
- Profit margin
- 15.6%
- Dividend yield
- —
- Beta
- 0.34
- Volume
- 416,363 avg 631,554
- 1-year return
- −22.0%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.1%
- 50-day average
- $49.51
- 200-day average
- $55.11
- Next earnings
- Nov 5 before open
- Shares outstanding
- 47.37M
Prestige Consumer Healthcare swing-trade checklist
Prestige Consumer Healthcare scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $49.00 is below the 50-day ($49.51) and 200-day ($55.11) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
54.6, Neutral
Reading 54.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
45.8% below
Price is 45.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.3% on average
From this point in the calendar, the next 20 trading days averaged +7.3% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Prestige Consumer Healthcare stock chart and price history
Prestige Consumer Healthcare closed at $49.00 on Oct 12, 2026, −22.0% over the past year, inside a 52-week range of $42.62 to $71.07.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +4.4%
- 3 months
- +3.8%
- 6 months
- −13.8%
- 1 year
- −22.0%
The full PBH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PBH in Gekko
Follow Prestige Consumer Healthcare through every session
Put PBH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PBH in GekkoFree for 7 days. No credit card required.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare develops, manufactures, markets and sells over-the-counter health and personal care products for shoppers in the United States and abroad. Its portfolio spans pain relief, infant care, sore throat relief, eye care, wart treatment, dental care, earwax removal, motion sickness, digestive health, cough relief, feminine hygiene, lice treatment, nasal care and rehydration products, with names such as BC, Goody's, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, DenTek, Dramamine, Fleet, Gaviscon, Monistat and Nix among its brands.
The business is organized into two segments, covering North American and International over-the-counter healthcare, and its goods are sold through outlets including mass merchants, drugstores, grocery chains, dollar and club stores, convenience stores and online retailers.
The company traces its roots to 1996 and is headquartered in Tarrytown, New York; it previously operated as Prestige Brands Holdings before adopting its current name in August 2018. Shares of Prestige Consumer Healthcare trade on the NYSE under the ticker PBH.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- prestigebrands.com
Prestige Consumer Healthcare GekkoIndex: the smart money zone
Prestige Consumer Healthcare’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.6, in the Neutral zone, down 10 points over five sessions.
54.6Neutral
Down 10 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 55 | 0.0% | −0.6% | ||
| Accumulation | 253 | −0.4% | −0.1% | ||
| Neutral (current zone) | 325 | 0.0% | −1.5% | ||
| Distribution | 41 | +0.7% | +1.7% | ||
| Selling | 8 | Too few readings yet | |||
Average PBH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PBH price, zone by zone.Track PBH in Gekko
Is Prestige Consumer Healthcare stock overvalued? Gekko Fair Value
Prestige Consumer Healthcare trades 45.8% below Gekko Fair Value of $90.45, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Prestige Consumer Healthcare shares are worth, recalculated every trading day.
$90.45
Gekko Fair Value, Oct 10, 2026
45.8% Undervalued
At the end of Aug 2026 the price was 16.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PBH in Gekko
Prestige Consumer Healthcare insider and Congress trading
No open-market insider purchases were filed for Prestige Consumer Healthcare, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PBH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PBH, plotted on the chart in Gekko.Open PBH in Gekko
Buybacks
Prestige Consumer Healthcare has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $2.66M
- As a share of market cap
- 0.11%
- Trailing four quarters
- $124.2M
From company filings.
Prestige Consumer Healthcare earnings: next date and track record
Prestige Consumer Healthcare reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- $1.07
- Revenue estimate
- $329.1M
5 of 8reports beat the EPS estimate
±5.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 5, 2026 AI summary
- What they said
- Prestige Consumer Healthcare reported Q3 fiscal 2026 results with $283.4M sales, down ~2.4% YoY, driven mainly by Clear Eye supply constraints and softness in analgesics and cough/cold categories. Gross margin was 55.5%, adjusted EPS $1.14 (vs $1.22 prior year), adjusted EBITDA margin low-30s, and YTD free cash flow $209M (up 13%). Company repurchased ~$46M shares and acquired Pillar Five. Management narrowed fiscal 2026 revenue outlook to approximately $1.1B, EPS to ~$4.54, and free cash flow expectation to $245M+. ClearEye supply has sequential improvement; restocking expected to continue into FY2027. Management noted consumer channel shifts, retailer destocking and volatility; e-commerce consumption grew >10% in Q3. Company wrote off ~$10M supplier loan. Capital allocation: prioritize brand investment, evaluate M&A, continue share repurchases when attractive. Guidance provided for FY26. Risks include supply chain constraints, inflation, geopolitical events, government announcements (acetaminophen), retailer order volatility, and supplier bankruptcy leading to loan loss.
- Guidance
- Fiscal 2026: narrowed sales outlook to ~ $1.1 billion; adjusted diluted EPS approx. $4.54; free cash flow of $245 million or more.
- Risks flagged
- Supply chain constraints (Clear Eye supply), high inflation, geopolitical events, government announcements impacting categories (acetaminophen), retailer order volatility/destocking, supplier credit loss (written off ~$10M), macro uncertainty.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 5, 2026 | $1.14 est $1.16 | $283.4M est $282.2M | −1.0% |
| Nov 6, 2025 | $1.07 est $0.97 | $274.1M est $294.2M | +0.2% |
| Aug 7, 2025 | $0.95 est $1.01 | $249.5M est $275.0M | −12.7% |
| May 8, 2025 | $1.32 est $1.30 | $296.8M est $270.4M | +7.2% |
| Feb 6, 2025 | $1.22 est $1.16 | $290.3M est $289.8M | +14.3% |
| Nov 7, 2024 | $1.09 est $1.08 | $283.5M est $282.1M | +3.5% |
| Aug 8, 2024 | $0.90 est $0.86 | $267.1M est $260.5M | −2.4% |
| May 14, 2024 | $0.98 est $1.14 | $277.0M est $287.4M | −5.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Prestige Consumer Healthcare stock forecast and analyst price targets
Analysts’ average 12-month price target for Prestige Consumer Healthcare is $67.80, +38.4% from the last close, from 1 firm rating the stock in the last 90 days.
$67.80consensus 12-month target, +38.4% from the last close
Each firm’s latest rating in the last 90 days: 1 firm.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 6 | William Blair | — | — |
−1.5%average 20-day move after past Neutral readings
+7.3%average move over the next 20 trading days in the last 5 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Prestige Consumer Healthcare seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Prestige Consumer Healthcare averaged +7.3% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.4% | 5 of 5 |
| Next 10 trading days | +4.0% | 5 of 5 |
| Next 15 trading days | +4.3% | 4 of 5 |
| Next 20 trading days | +7.3% | 4 of 5 |
| Next 30 trading days | +7.7% | 3 of 5 |
For scale, PBH’s typical 20-trading-day move in either direction is about 5.1%.
Prestige Consumer Healthcare market cap and key statistics
Prestige Consumer Healthcare’s market cap is $2.32B, with a P/E ratio of 13.5 and revenue of $1.10B over the last twelve months.
Valuation
- Market cap
- $2.32B
- P/E ratio
- 13.5
- Forward P/E
- 10.6
- EPS, TTM
- $3.57
- Gekko Fair Value
- $90.45
Trading
- Volume
- 416,363
- Avg volume, 20 days
- 631,554
- 52-week high
- $71.07
- 52-week low
- $42.62
- Shares outstanding
- 47.37M
Financials
- Revenue, TTM
- $1.10B
- Profit margin
- 15.6%
- Return on equity
- 9.1%
- Quarterly earnings growth, YoY
- −35.8%
Risk and income
- Beta
- 0.34
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.1%
Prestige Consumer Healthcare stock news this week
Coverage of Prestige Consumer Healthcare this week reads positive: 2 positive, 1 neutral and 1 negative headlines.
- Prestige Consumer Healthcare acquires Breathe Right for $1.045bnscanx.trade, Oct 9
- Prestige prices $400 million 6.25% notes due 2034scanx.trade, Oct 8
- Prestige Consumer Healthcare stock falls 11% on Q4 revenue declinescanx.trade, Oct 8
- Transcript: Prestige Consumer Q1 2027 Earnings Conference CallBenzinga, Oct 7
Prestige Consumer Healthcare peers
Prestige Consumer Healthcare’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Prestige Consumer Healthcare stock FAQ
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.32B at the Oct 12, 2026 close of $49.00, with 47.37M shares outstanding. The shares trade on a P/E ratio of 13.5.
What is the Prestige Consumer Healthcare stock forecast?
The consensus analyst 12-month price target for Prestige Consumer Healthcare is $67.80, +38.4% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Prestige Consumer Healthcare stock overvalued or undervalued?
On Gekko’s estimate Prestige Consumer Healthcare is undervalued: the Oct 12, 2026 close of $49.00 is 45.8% below Gekko Fair Value of $90.45. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Prestige Consumer Healthcare report earnings next?
Prestige Consumer Healthcare is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of $1.07 per share on revenue of $329.1M. Prestige Consumer Healthcare beat the earnings estimate in 5 of its last 8 reports, moving 5.9% on average across the report.
What is Prestige Consumer Healthcare’s 52-week high and low?
Prestige Consumer Healthcare’s 52-week high is $71.07 and its 52-week low is $42.62; it closed at $49.00 on Oct 12, 2026, −22.0% over the past year. Over the last five years the shares peaked at $90.04 on Mar 10, 2025.
Is Prestige Consumer Healthcare stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Prestige Consumer Healthcare the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.